# ERN RARE-LIVER prospective research registry

First published: 01/02/2024

Last updated: 17/10/2024

Data source Human Disease registry Other

## Administrative details

## Administrative details

#### Data source ID

40246

#### Data source acronym

R-LIVER rare liver disease registry

#### Data holder

University Medical Centre Hamburg-Eppendorf

#### Data source type

Disease registry Other

#### Data source type, other

Prospective studies database

#### Main financial support

European public funding

#### **Care setting**

Hospital inpatient care Hospital outpatient care Primary care – specialist level (e.g. paediatricians) Secondary care – specialist level (ambulatory)

#### **Data source qualification**

If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.

No

#### Data source website

https://rare-liver.eu/registry

## Contact details

#### Christoph Schramm ERN.RareLiver@uke.de

Main

ERN.RareLiver@uke.de

### Data source regions and languages

#### **Data source countries**

Argentina

Belgium

Canada

Czechia

Denmark

Germany

Greece

Hungary

Israel

Italy

Lithuania

Netherlands

Poland

Slovakia

Spain

Switzerland

United Kingdom

#### Data source languages

English

### Data source establishment

#### Data source established

15/06/2018

#### Data source time span

First collection: 01/05/2017

The date when data started to be collected or extracted.

## Studies

## List of studies that have been conducted using the data source

Survey on the collection of data on adverse events related to medicinal products through registries

## Data elements collected

## The data source contains the following information

#### **Disease information**

Does the data source collect information with a focus on a specific disease? This might be a patient registry or other similar initiatives.

Yes

#### **Disease details**

Autoimmune hepatitis Primary biliary cholangitis Polycystic liver disease Portal vein thrombosis

#### **Disease details (other)**

Primary sclerosing cholangitis (PSC), polycystic liver disease, biliary artresia, Budd-Chiari-Syndrome (BCS), Non cirrohtic portal hypertension (NCPIH), Sinusoidal Obstruction Syndrome (SOS)

#### **Rare diseases**

Are rare diseases captured? In the European Union a rare disease is one that affects no more than 5 people in 10,000.

#### Yes

#### **Pregnancy and/or neonates**

Does the data source collect information on pregnant women and/or neonatal subpopulation (under 28 days of age)?

Yes

#### Hospital admission and/or discharge

No

#### **ICU** admission

Is information on intensive care unit admission available?

No

#### **Cause of death**

Captured

#### Cause of death vocabulary

Not coded (Free text)

#### **Prescriptions of medicines**

Captured

#### **Dispensing of medicines**

Not Captured

#### Advanced therapy medicinal products (ATMP)

Is information on advanced therapy medicinal products included? A medicinal product for human use that is either a gene therapy medicinal product, a somatic cell therapy product or a tissue engineered products as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2007 Art 1(1)].

No

#### Contraception

Is information on the use of any type of contraception (oral, injectable, devices etc.) available?

No

#### Indication for use

Does the data source capture information on the therapeutic indication for the use of medicinal products?

Captured

#### Indication vocabulary

Not coded (Free text)

#### **Medical devices**

Is information on medicinal devices (e.g., pens, syringes, inhalers) available?

No

#### Administration of vaccines

No

#### Procedures

Does the data source capture information on procedures (e.g., diagnostic tests, therapeutic, surgical interventions)?

Captured

#### **Procedures vocabulary**

Not coded (Free text)

#### Healthcare provider

Is information on the person providing healthcare (e.g., physician, pharmacist, specialist) available? The healthcare provider refers to individual health professionals or a health facility organisation licensed to provide health care diagnosis and treatment services including medication, surgery and medical devices.

No

#### **Clinical measurements**

Is information on clinical measurements (e.g., BMI, blood pressure, height) available?

Yes

#### **Genetic data**

Are data related to genotyping, genome sequencing available?

Not Captured

#### **Biomarker data**

Does the data source capture biomarker information? The term "biomarker" refers to a broad subcategory of medical signs ( objective indications of medical state observed from outside the patient), which can be measured accurately and reproducibly. For example, haematological assays, infectious disease markers or metabolomic biomarkers.

Captured

#### Biomarker data vocabulary

Other

#### Biomarker vocabulary, other

Not coded (free text)

#### **Patient-reported outcomes**

Is information on patient-reported outcomes (e.g., quality of life) available?

No

#### **Patient-generated data**

Is patient-generated information (e.g., from wearable devices) available?

#### No

#### Units of healthcare utilisation

Are units of healthcare utilisation (e.g., number of visits to GP per year, number of hospital days) available or can they be derived? Units of healthcare utilisation refer to the quantification of the use of services for the purpose of preventing or curing health problems.

No

#### **Unique identifier for persons**

Are patients uniquely identified in the data source?

Yes

#### **Diagnostic codes**

Captured

#### Diagnosis / medical event vocabulary

ICD

#### **Medicinal product information**

Captured

#### Medicinal product information collected

Active ingredient(s)

Dose

#### Medicinal product vocabulary

Not coded (Free text)

#### **Quality of life measurements**

Not Captured

#### Lifestyle factors

Captured

#### Lifestyle factors

Alcohol use

Tobacco use

#### Sociodemographic information

Captured

#### Sociodemographic information collected

Age

Ethnicity

Gender

## Quantitative descriptors

## Population Qualitative Data

#### Population age groups

Paediatric Population (< 18 years) Preterm newborn infants (0 – 27 days) Term newborn infants (0 – 27 days) Infants and toddlers (28 days – 23 months) Children (2 to < 12 years) Adolescents (12 to < 18 years) Adults (18 to < 46 years) Adults (46 to < 65 years) Elderly ( $\geq$  65 years) Adults (65 to < 75 years) Adults (75 to < 85 years) Adults (85 years and over)

## Estimated percentage of the population covered by the data source in the catchment area

We are not able to provide the percentage of population covered since this number is unknown.

### Description of the population covered by the data source in the catchment area whose data are not collected (e.g., people who are registered only for private care)

Regional sub-set - Data capture is restricted to participating centres in each country that are members and partners of European Reference Network on Hepatological, and thus do not represent nation-wide data sets.

## Population

**Population size** 

1678

#### Active population size

1534

## Population by age group

Age group	Population size	Active population size
Paediatric Population (< 18 years)	162	154
Preterm newborn infants (0 – 27 days)	0	0
Term newborn infants (0 – 27 days)	0	0
Infants and toddlers (28 days – 23 months)	8	7
Children (2 to < 12 years)	43	41
Adolescents (12 to < 18 years)	111	106
Adults (18 to < 46 years)	501	456
Adults (46 to < 65 years)	667	619
Elderly (≥ 65 years)	348	305
Adults (65 to < 75 years)	252	224
Adults (75 to < 85 years)	85	74
Adults (85 years and over)	11	7

## Median observation time

## Median time (years) between first and last available records for unique individuals captured in the data source

1.00

Median time (years) between first and last available records for unique active individuals (alive and currently registered) capt

1.00

## Data flows and management

## Access and validation

#### Governance details

Documents or webpages that describe the overall governance of the data source and processes and procedures for data capture and management, data quality check and validation results (governing data access or utilisation for research purposes).

https://rare-liver.eu/about/governance

#### **Biospecimen access**

Are biospecimens available in the data source (e.g., tissue samples)?

No

#### Access to subject details

Can individual patients/practitioners/practices included in the data source be contacted?

Yes

#### **Description of data collection**

eCRFs based on CastorEDC

## Event triggering registration

#### Event triggering registration of a person in the data source

Disease diagnosis

## Event triggering de-registration of a person in the data source

Death Loss to follow up Other

#### Event triggering de-registration of a person in the data source, other

Liver transplantation; study opt-out

#### Event triggering creation of a record in the data source

Updates of the exisiting patient entry are triggered by a yearly follow-up visit at the treating hospital

## Data source linkage

#### Linkage

Is the data source described created by the linkage of other data sources (prelinked data source) and/or can the data source be linked to other data source on an ad-hoc basis?

No

# Data management specifications that apply for the data source

#### Data source refresh

Quarterly

#### Informed consent for use of data for research

Other

#### Possibility of data validation

Can validity of the data in the data source be verified (e.g., access to original medical charts)?

Yes

#### **Data source preservation**

Are records preserved in the data source indefinitely?

Yes

#### **Approval for publication**

Is an approval needed for publishing the results of a study using the data source?

Yes

#### Informed consent, other

There is a committee to evaluate requests for data access

#### Data source last refresh

24/05/2021

## Common Data Model (CDM) mapping

#### **CDM** mapping

Has the data source been converted (ETL-ed) to a common data model?

No